Paxlovid did not beat placebo in Stanford-led long Covid study

Paxlovid, a COVID-19 antiviral treatment developed by Pfizer, did not provide significant relief from long COVID symptoms in a recent study conducted by researchers at Stanford University. The study, which was funded by Pfizer and involved 155 participants, found that a 15-day course of Paxlovid did not significantly improve symptoms compared to a placebo. The researchers concluded that Paxlovid did not demonstrate a significant benefit in reducing symptoms of long COVID, which includes fatigue, brain fog, shortness of breath, body aches, gastrointestinal symptoms, and cardiovascular symptoms.